AU3151097A - Pharmaceutical for treating of neurological and neuropsychiatric disorders - Google Patents

Pharmaceutical for treating of neurological and neuropsychiatric disorders

Info

Publication number
AU3151097A
AU3151097A AU31510/97A AU3151097A AU3151097A AU 3151097 A AU3151097 A AU 3151097A AU 31510/97 A AU31510/97 A AU 31510/97A AU 3151097 A AU3151097 A AU 3151097A AU 3151097 A AU3151097 A AU 3151097A
Authority
AU
Australia
Prior art keywords
neurological
pharmaceutical
treating
neuropsychiatric disorders
neuropsychiatric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU31510/97A
Other versions
AU737095B2 (en
Inventor
Stanley Charles Bell
Laurence Borden
Vassil Iliya Ognayanov
Jing Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire NPS Pharmaceuticals Inc
Original Assignee
TROPHIX PHARM Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TROPHIX PHARM Inc filed Critical TROPHIX PHARM Inc
Publication of AU3151097A publication Critical patent/AU3151097A/en
Application granted granted Critical
Publication of AU737095B2 publication Critical patent/AU737095B2/en
Assigned to NPS PHARMACEUTICALS, INC. reassignment NPS PHARMACEUTICALS, INC. Alteration of Name(s) in Register under S187 Assignors: ALLELIX NEUROSCIENCE, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
AU31510/97A 1996-05-31 1997-05-29 Pharmaceutical for treating of neurological and neuropsychiatric disorders Ceased AU737095B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US65584796A 1996-05-31 1996-05-31
US08/655847 1996-05-31
US80768197A 1997-02-27 1997-02-27
US08/807681 1997-02-27
PCT/US1997/009346 WO1997045423A1 (en) 1996-05-31 1997-05-29 Pharmaceutical for treating of neurological and neuropsychiatric disorders

Publications (2)

Publication Number Publication Date
AU3151097A true AU3151097A (en) 1998-01-05
AU737095B2 AU737095B2 (en) 2001-08-09

Family

ID=27097055

Family Applications (1)

Application Number Title Priority Date Filing Date
AU31510/97A Ceased AU737095B2 (en) 1996-05-31 1997-05-29 Pharmaceutical for treating of neurological and neuropsychiatric disorders

Country Status (5)

Country Link
EP (1) EP0918767A4 (en)
JP (2) JP4403212B2 (en)
AU (1) AU737095B2 (en)
CA (1) CA2255727A1 (en)
WO (1) WO1997045423A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0918767A4 (en) * 1996-05-31 2000-04-26 Allelix Neuroscience Inc Pharmaceutical for treating of neurological and neuropsychiatric disorders
EP1058684A1 (en) * 1998-03-06 2000-12-13 Janssen Pharmaceutica N.V. Glycine transport inhibitors
TW555757B (en) 1998-07-31 2003-10-01 Akzo Nobel Nv Aminomethylcarboxylic acid derivatives
HN1999000149A (en) 1998-09-09 2000-01-12 Pfizer Prod Inc DERIVATIVES OF 4,4-BIARILPIPERIDINA
UA75051C2 (en) 1999-09-03 2006-03-15 Syngenta Participations Ag Tetrahydropiridines as pesticides, a composition, a method for the preparation thereof and a method of controlling pests
TWI243173B (en) 1999-11-17 2005-11-11 Akzo Nobel Nv Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives
EP1318802A2 (en) 2000-09-08 2003-06-18 Gliatech, Inc. Substituted hydrazine derivatives
AU2001290786A1 (en) 2000-09-14 2002-03-26 Gliatech, Inc. Nitrogen-containing compounds and their use as glycine transport inhibitors
AR032653A1 (en) * 2001-02-09 2003-11-19 Telik Inc HYPERCYCLIC INHIBITORS OF THE GLICINE TRANSPORTER 2 PHARMACEUTICAL COMPOSITIONS, USE AND METHODS.
AU2002324283B2 (en) 2001-07-24 2008-02-21 Serono Genetics Institute S.A. Variants and exons of the GlyT1 transporter
AU2002332659A1 (en) * 2001-08-21 2003-03-03 Sepracor, Inc. 2-substituted piperidines that are ligands for monoamine receptors and transporters
WO2005100301A1 (en) * 2004-03-31 2005-10-27 Eli Lilly And Company 2-aryloxyethyl glycine derivatives and their use as glycine transport inhibitors
ES2326833T3 (en) * 2005-01-18 2009-10-20 F. Hoffmann-La Roche Ag METHANONE 2,5-DISUBSTITUTED PHENYL DERIVATIVES AS INHIBITORS OF THE GLYCIN CONVEYOR 1 (GLYT-1) FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS.
CA2655159C (en) * 2006-06-28 2014-12-30 Amgen Inc. Glycine transporter-1 inhibitors
AU2008335788B2 (en) 2007-12-12 2012-11-29 Amgen Inc. Glycine transporter-1 inhibitors
AU2009221310A1 (en) * 2008-03-05 2009-09-11 Neurosearch A/S Novel 4-benzhydryl-tetrahydro-pyridine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CN110372571B (en) * 2018-04-12 2022-11-15 中国科学院大连化学物理研究所 2- (2, 2-diarylethyl) -cyclic amine derivative or salt, synthesis and application thereof, and composition

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0686463B2 (en) * 1988-07-01 1994-11-02 明治製菓株式会社 Novel cephem compound, its production method and antibacterial agent
JPH03264562A (en) * 1989-05-22 1991-11-25 Hokuriku Seiyaku Co Ltd Piperidine derivative
CA2015949A1 (en) * 1989-05-22 1990-11-22 Yasuo Ito Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same
JPH03204885A (en) * 1989-12-28 1991-09-06 Meiji Seika Kaisha Ltd New cephalosporin based compound
US5057524A (en) * 1990-02-08 1991-10-15 A. H. Robins Company Incorporated 4-[diaryl)hydroxymethyl]-1-piperidinealkylcarboxylic acids, salts and esters useful in the treatment of allergic disorders
US5063235A (en) * 1990-04-30 1991-11-05 A. H. Robins Company, Inc. 4-[(diaryl)hydromethyl]-1-piperidinealkanols and esters and carbamates thereof useful in the treatment of allergic disorders
JPH0517443A (en) * 1991-07-11 1993-01-26 Hokuriku Seiyaku Co Ltd Piperidine derivative
EP0918767A4 (en) * 1996-05-31 2000-04-26 Allelix Neuroscience Inc Pharmaceutical for treating of neurological and neuropsychiatric disorders

Also Published As

Publication number Publication date
JP4403212B2 (en) 2010-01-27
JP2009149663A (en) 2009-07-09
EP0918767A1 (en) 1999-06-02
JP2001500107A (en) 2001-01-09
EP0918767A4 (en) 2000-04-26
CA2255727A1 (en) 1997-12-04
WO1997045423A1 (en) 1997-12-04
AU737095B2 (en) 2001-08-09

Similar Documents

Publication Publication Date Title
HUP0100815A3 (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
AU4645596A (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
IL133800A0 (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
AU2736097A (en) Method for preparation of compounds useful for prevention and treatment of central nervous system disorders
AU4585996A (en) Pyrazolopyrimidines for treatment of neuronal and other disorders
HUP9904525A3 (en) Pharmaceutical compositions for the treatment of neurological disorders comprising s-(-)-n-propargyl-1-amino indan
EP0946485A4 (en) Method for treatment of dermatological disorders
IL116998A0 (en) Novel indoline compounds processes for their preparation and their use for the treatment of CNS disorders
AU5750796A (en) System for the treatment of insomnia
AU3151097A (en) Pharmaceutical for treating of neurological and neuropsychiatric disorders
AU4868599A (en) Composition for and method of treating neurological disorders
AUPO274596A0 (en) Method for the treatment of neurological or neuropsychiatric disorders
PL316528A1 (en) Pharmaceutic compositions and drugs for prevetion and treatment of endothelial disorders
EP0750909A4 (en) The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence
AU5383196A (en) Pharmaceutical compositions for prevention and treatment of central nervous system disorders
AU1578295A (en) Use of arylcyclobutylalkylamines for the treatment of seizures and neurological disorders
AU3046897A (en) Uridine-comprising therapeutic active agent for treatment of neurodegenerative disorders
PL332313A1 (en) Application of benzopyranoles in treatment of neurological disorders
AU5198898A (en) Method for treatment of glutamate related disorders
AU8369998A (en) Medicinal product and method for treatment and prevention of cognitive disorders
AUPN104895A0 (en) Methods of and preparations for the treatment of ailments and disorders
ZA985818B (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders.
HK1044900A1 (en) Method for the treatment of neurological or neuropsychiatric disorders
AU2245695A (en) Composition for treating neurological disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)